Avanir sues Impax over planned Nuedexta generic, Bloomberg reports Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
Impax reports Q4 adjusted EPS 16c, consensus 12c Reports Q4 revenue $131.2M, consensus $125.47M. Reports Q4 Global Pharmaceuticals revenue $117.9M. The increase is due to higher sales of several key generic products as well as the impact of customer credits that were recorded in the prior year period of $19.2 million as a result of customer credits relating to certain pricing activities.